The 72-year-old patient was unable to mount her own immune defense against the SARS-CoV-2 virus because of chronic lymphocytic leukemia, which compromises normal immunity and immunoglobulin production.A 72-year-old woman was hospitalized with severe COVID-19 disease, 33 days after the onset of symptoms. She was suffering a prolonged deteriorating illness, with severe pneumonia and a high risk of death, and she was unable to mount her own immune defense against the SARS-CoV-2 virus because of chronic lymphocytic leukemia, which compromises normal immunoglobulin production.
But when physicians at the University of Alabama at Birmingham recommended a single intravenous infusion of convalescent blood plasma from her son-in-law — who had recovered from COVID-19 disease — a remarkable, beneficial change followed. Her physician, Randall Davis, M.D., professor in the UAB Department of Medicine and senior scientist at the O'Neal Comprehensive Cancer Center, says she showed prompt and profound improvement within 48 hours.
Her 104-degree F fever rapidly dropped. In three days, the virus was no longer detectable in her respiratory swabs. And four days after the infusion, she was discharged from the hospital.
However, this single case appears to be an outlier, as shown through collaborative research at UAB, the University of Pennsylvania and several other institutions. In their study, reported in Cell Reports Medicine, researchers show that the woman’s recovery was due to an extremely high virus-neutralizing titer in the son-in-law’s donated plasma that she received. They found that this titer was higher than titers they measured in 64 other remnant convalescent plasmas collected by two blood banks.
Only 37 percent of the convalescent plasmas from the first blood bank had neutralizing antibody titers above 250, the lower cut-off value allowed by the Food and Drug Administration’s emergency use authorization for convalescent plasma, which allows an unapproved medical product to be used in an emergency to treat life-threatening disease. In the plasmas from the second blood bank, only 47 percent exceeded the neutralizing antibody titer cut-off of 250. Thus, many of these plasmas were inadequate for transfusion.
While eight convalescent plasmas from the second blood bank exceeded a neutralizing antibody titer of 1,000, they were far beneath the extremely high, 5,720 neutralizing antibody titer of the son-in-law’s plasma that was given to his immunodeficient COVID-19 mother-in-law.
The researchers also analyzed plasma titers in 17 other patients besides the 72-year-old woman, both before and after they were given convalescent plasma for treatment of COVID-19. Before infusion of plasma, 53 percent of these patients already had neutralizing antibody values greater than 250, and seven of the patients had titers greater than 3,000.
Randall Davis, M.D.For the 16 patients the researchers were able to analyze, the infusion of convalescent plasma had no significant impact on their preexisting neutralizing antibody titers, and many of the recipients had endogenous neutralizing antibody responses that far exceeded those of the administered convalescent plasma units.
In contrast, the infusion of 218 milliliters of the son-in-law’s convalescent plasma into the index COVID-19 patient, an amount equal to about one cup, resulted in an obvious rise in her neutralizing antibody titers that persisted four days after infusion.
“Our results have important implications for how convalescent plasma therapy is being used now and how it may be improved,” Davis and colleagues reported. “The low neutralizing titers in most convalescent plasma donors raise concern.
“Convalescing individuals with truly high-titer neutralizing antibodies are rare, which underscores the need for a concerted effort to identify them but also poses the question of whether there are ample numbers of suitable convalescent plasma donors,” they wrote. “The generally low neutralizing antibody titers in most donors, as well as high titer baseline neutralizing antibodies in many recipients, highlight the importance of first testing the convalescent plasmas, and also the recipients. Doing so should optimize the clinical benefit and reduce the effort spent when convalescent plasma therapy is not appropriate.”
Co-first authors of the study are Kazuhito Honjo, DVM, Ph.D., UAB Department of Medicine, and Ronnie M. Russell, University of Pennsylvania Department of Medicine. Co-corresponding authors are Davis, UAB Department of Medicine, and Beatrice H. Hahn, M.D., University of Pennsylvania Department of Medicine.
Other authors are Ran Li, Edlue M. Tabengwa, Yutao Hua, Lynn Prichard, Sarah Sterrett, Todd P. McCarty, Paul A. Goepfert and Sonya L. Heath, UAB Department of Medicine; Weimin Liu and Regina Stoltz, University of Pennsylvania Department of Medicine; Ashton N. Kornbrust, Marisa B. Marques and Jose L. Lima, UAB Department of Pathology; Chris M. Lough, LifeSouth Community Blood Centers, Gainesville, Florida; Thomas J. Ketas and John P. Moore, Weill Medical College of Cornell University; Theodora Hatziioannou and Paul D. Bieniasz, The Rockefeller University, New York City; and David T. Redden, UAB Department of Biostatistics.
Support came from the UAB School of Medicine Dean’s office COVID-19 research initiative, the UAB Cancer Immunobiology Program, and from National Institutes of Health grants AI069452, AI110553, AI036082 and AI150590.